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Abstract Topical corticosteroids are routinely used
as postoperative ocular anti-inflammatory drugs; how-
ever, adverse effects such as increased intraocular
pressure (IOP) are observed with their use. While older
corticosteroids such as dexamethasone and predniso-
lone acetate offer good anti-inflammatory efficacy,
clinically significant increases in IOP (C10 mmHg)
are often associated with their use. Loteprednol eta-
bonate, a novel C-20 ester-based corticosteroid, was
retrometabolically designed to offer potent anti-
inflammatory efficacy but with decreased impact on
IOP. After exerting its therapeutic effects on the site of
action, loteprednol etabonate is rapidly converted to
inactive metabolites, resulting in fewer adverse effects.
Randomized controlled studies have demonstrated the
clinical efficacy and safety of loteprednol etabonate
ophthalmic suspension 0.5 % for the treatment of
postoperative inflammation in post-cataract patients
with few patients, if any, exhibiting clinically signif-
icant increases (C10 mmHg) in IOP. Furthermore,
safety studies demonstrated a minimal effect of
loteprednol etabonate on IOP with long-term use or
in steroid responders with a much lower propensity to
increase IOP relative to prednisolone acetate or
dexamethasone. The anti-inflammatory treatment
effect of loteprednol etabonate appears to be similar
to that of rimexolone and difluprednate with less
impact on IOP compared to difluprednate, although
confirmatory comparative studies are needed. The
available clinical data suggest that loteprednol etabon-
ate is an efficacious and safe corticosteroid for the
treatment of postoperative inflammation.
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Background
Ocular inflammation is common after ophthalmic
surgery, particularly after surgical removal of cataracts
combined with intraocular lens (IOL) implantation.
This inflammatory response includes the metabolism
of arachidonic acid to prostaglandins and leukotrienes
and the recruitment of neutrophils and macrophages to
the site of surgical trauma [1]. This process eventually
manifests as a mild iritis, corneal edema, and increased
cells and proteins (flare) in the anterior chamber of the
eye, accompanied by hyperalgesia [2]. While recent
advances in surgical techniques (smaller incisions),
more efficient phacoemulsifiers, and improved viscoe-
lastics have improved cataract surgery outcomes,
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postoperative inflammation and pain remain a major
source of discomfort for patients. If left untreated,
postoperative inflammation can lead to suboptimal
vision results or complications such as cystoid macular
edema (CME) [1, 3–6]. As surgical techniques have
improved, so has patient demand for excellent postop-
erative vision without postoperative complications.
Ocular inflammation following cataract surgery is
managed by topical anti-inflammatory drugs such as
non-steroidal anti-inflammatory drugs (NSAIDs) and/
or corticosteroids. Both are effective in resolving
postoperative inflammation and pain, increasing patient
comfort, and decreasing the risk of complications [1, 7–
11]. NSAIDs act through inhibition of cyclooxygenase
enzymes, thereby blocking the production of prosta-
glandins [12]. Corticosteroids have a broader mecha-
nism of action. They inhibit phospholipase A2 in the
inflammatory cascade, which converts membrane phos-
pholipids to arachidonic acid, thereby inhibiting the
cyclooxygenase and lipoxygenase pathways and the
formation of all eicosanoids. Corticosteroids suppress
both the early (capillary dilation, increased vascular
permeability, recruitment of leukocytes) and late (depo-
sition of fibrin, proliferation of inflammatory cells and
chemokines) phases of inflammation [13–16]. How-
ever, they are also associated with side-effects, includ-
ing steroid-induced intraocular pressure (IOP)
elevation, lowered resistance to infection, risk of
cataract formation, and decreased wound healing [16–
20]. Of these, increased IOP is the most significant side-
effect for the post-cataract patient, and is thought to be
due to structural and biochemical changes in the
trabecular meshwork causing increased resistance to
aqueous humor outflow [21]. Steroid-induced IOP
elevation has been reported to occur in 18–36 % of
patients, termed steroid responders, [15, 22] with risk
factors including a history of glaucoma, a familial
predisposition toward glaucoma, or high myopia [22,
23]. Older corticosteroids, such as prednisolone and
dexamethasone, are associated with a greater impact on
IOP compared to newer corticosteroids [24].
Recent research indicates that NSAIDs may have a
synergistic effect with corticosteroids, particularly for
the prevention of CME. In most instances, NSAIDs are
used in combination with topical ocular corticoste-
roids [25]. It is therefore vital for ophthalmic surgeons
to be able to provide patients with a corticosteroid
option that offers high efficacy yet does not result in an
increase of IOP to clinically significant levels.
Loteprednol etabonate is a novel corticosteroid
produced by retrometabolic design. In retrometabolic
drug design, an inactive and nontoxic metabolite of a
reference compound is utilized as a starting point for
conversion to a therapeutically active, metabolically
labile compound [26]. Loteprednol etabonate was
designed starting with D1 cortienic acid, an inactive
metabolite of prednisolone. Structurally, loteprednol
etabonate differs from prednisolone in that the ketone
at the carbon-20 (C-20) position is replaced with a
chloromethyl ester and the 17a-hydroxyl group is
replaced with a carbonate moiety (Fig. 1). After
exerting its effects, loteprednol etabonate is rapidly
metabolized by tissue esterases to D1 cortienic acid
etabonate and then to D1 cortienic acid, thereby
limiting any potential adverse effects associated with
its use. Preclinical studies demonstrated that lotepred-
nol etabonate is highly lipophilic and has strong
binding affinity to glucocorticoid receptors. Indeed, its
lipophilicity was found to be 10 times greater while its
binding affinity to the glucocorticoid receptor was
found to be 4.3 times greater than that of dexameth-
asone [27, 28]. Approved in the United States in 1998
for the treatment and prevention of various steroid-
responsive ocular inflammatory conditions as well as
for the treatment of postoperative ocular inflamma-
tion, loteprednol etabonate has since received mar-
keting approval in various countries across Europe,
Latin America, the Middle East, North Africa, and
Asia.
The objective of this paper was to review the
available published clinical data on loteprednol
etabonate suspension 0.5 % in the treatment of
Fig. 1 Loteprednol
etabonate (I) and its inactive
metabolites, D1 cortienic
acid etabonate (II) and D1
cortienic acid (III)
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postoperative inflammation and pain, and to assess its
efficacy and safety along with that of other cortico-
steroids formally studied and approved for the treat-
ment of postoperative inflammation, namely,
difluprednate and rimexolone. Publications on lote-
prednol etabonate were identified through MEDLINE
searches (1950 onwards) using the terms loteprednol,
postoperative pain, inflammation, cataract, and cata-
ract surgery. In order to identify publications about
other corticosteroids currently used in postoperative
pain and inflammation, the terms rimexolone, diflu-
prednate, prednisolone, dexamethasone, fluorometho-
lone, cataract, cataract surgery, postoperative, and
postsurgical inflammation were also searched. Only
ophthalmic studies were included, and validity was
assessed based on dosage form (topical only), indica-
tions for use, study endpoints, and year of publishing.
The search was limited to English language, peer-
reviewed primary studies and any reviews published in
the last 5 years. Additional references were obtained
by searching reference lists of identified articles. As no
direct head-to-head studies comparing loteprednol
etabonate to rimexolone or to difluprednate were
found, insights on comparative safety and efficacy of
loteprednol etabonate, rimexolone, and difluprednate
were drawn from vehicle-controlled studies or from
studies in which these newer corticosteroids were
compared to older corticosteroids such as dexameth-
asone and/or prednisolone acetate.
Loteprednol etabonate: efficacy and safety studies
The efficacy and safety of loteprednol etabonate
ophthalmic suspension 0.5 % for the treatment of
postoperative inflammation has been demonstrated by
several studies over the last decade (Table 1).
A double-masked, vehicle-controlled evaluation of
the efficacy and safety of loteprednol etabonate for
postoperative inflammation after cataract removal
with IOP implantation was conducted in 1998 by the
Loteprednol Etabonate Postoperative Study Group
[2]. In this study, 203 patients with an anterior
chamber inflammation (ACI) severity C3 (0–9 scale)
on the day following cataract surgery were random-
ized to either loteprednol etabonate or vehicle admin-
istered four times daily in the operated eye for
14 days. Resolution of ACI, defined as B5 cells and
none-to-trace flare, was observed in 55 % of patients
in the loteprednol etabonate group and 28 % of
Table 1 Studies demonstrating the efficacy and safety of loteprednol etabonate (LE) 0.5 % for postoperative inflammation
Study parameters Stewart et al. [13] LE postoperative study




Comparator Vehicle Vehicle 1 % (PA) Fluorometholone
acetate 0.1 %
(FA)
No. of patients 203 227 20 30
Treatment duration
(weeks)
2 2 4 2
Patients with
resolution of
ACIa at final visit (%)
LE group—64 LE group—55 LE group—60 LE group—60
Vehicle—29 Vehicle—28 PA group—50 FA group—100
Mean IOP at final visit Mean decrease in IOP of
1–2 mmHg for both
treatment groups
Mean decrease in IOP of
1–2 mmHg for both
treatment groups
LE group—
12 ± 3 mmHg
Not reported
PA group—




n = 3 for loteprednol
etabonate; n = 0
for vehicle
n = 0 for loteprednol
etabonate; n = 1
for vehicle
Not reported Not reported
ACI anterior chamber inflammation, IOP intraocular pressure, LE loteprednol etabonate, PA prednisolone acetate,
FA fluorometholone acetate
a Resolution of ACI defined as anterior chamber cell count \5 and flare Grade 0 (none)
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patients in the vehicle group (27 % difference,
P \ 0.001) at the final visit. The rate for individual
signs of cell and flare as well as supportive signs and
symptoms of chemosis, erythema, bulbar injection,
ciliary flush, pain, photophobia, tearing and discom-
fort, all favored the loteprednol etabonate group
(P \ 0.05). From a safety perspective, both treatment
groups exhibited a mean decrease in IOP (1–2 mmHg)
when compared with baseline. No patients in the
loteprednol etabonate group versus a single patient in
the vehicle group exhibited a clinically significant
increase in IOP (C10 mmHg). Stewart et al. [13]
conducted an identical study to evaluate the efficacy
and safety of loteprednol etabonate in controlling ACI.
In this study, 227 post-cataract patients with ACI
severity C3 (0–9 scale) on the day following surgery
were randomized to loteprednol etabonate or vehicle.
Resolution of ACI at the final visit was observed in
64 % of patients in the loteprednol etabonate and
29 % of patients in the vehicle groups (35 % differ-
ence, P \ 0.001). Again, the resolution rate for cells
and flare individually as well as supportive signs and
symptoms of chemosis, erythema, bulbar injection,
ciliary flush, pain, photophobia, tearing, and discom-
fort all favored the loteprednol etabonate group
(P \ 0.05). As in the first study, mean IOP decreased
in both treatment groups relative to baseline by
1–2 mmHg. A clinically significant increase in IOP
(C10 mmHg) was observed in three patients in the
loteprednol etabonate group. Comstock and Usner
[29] further explored the efficacy of loteprednol
etabonate in resolving pain and discomfort in these
studies. The treatment effect for pain and discomfort
was 31 and 43 %, respectively, for the first study and
24 and 30 %, respectively, for the second study.
Analysis of pooled data indicated that the proportion
of at-risk patients with resolution of pain at the final
visit was 84 % for the loteprednol etabonate group and
56 % for the placebo group (P \ 0.05). Similarly,
resolution of discomfort at the final visit was 79 % for
the loteprednol etabonate group and 42 % for the
placebo group (P \ 0.05).
Three small prospective studies further compared
the efficacy and/or safety of loteprednol etabonate
with that of other corticosteroids. Stewart [30] com-
pared the efficacy and safety of loteprednol etabonate
0.5 % and fluorometholone acetate 0.1 % in the
treatment of postoperative inflammation. A total of
30 post-cataract patients were enrolled in this
randomized, double-masked, parallel-group study.
All patients instilled a single drop of the assigned
study medication four times daily for 14 days. At the
final visit, no statistically significant differences in
flare, anterior segment cell, or conjunctival hyperemia
were observed between the two treatment groups. No
significant adverse events were observed in either
group. Grigorian et al. [31] compared the efficacy and
safety of loteprednol etabonate and prednisolone
acetate 1 %, in the treatment of postoperative inflam-
mation following cataract surgery. Twenty patients
were randomly assigned to loteprednol etabonate or
prednisolone, instilled four times daily for the first
week, tapering to once daily by week 4, in this
randomized double-masked study. Patients from both
groups achieved a similar resolution of postoperative
inflammation (conjunctival hyperemia, corneal edema,
aqueous cells, flare), with 60 % of patients in the
loteprednol etabonate group and 50 % of patients in the
prednisolone group achieving significant resolution of
inflammation by the final visit. Despite the study’s
small sample size, treatment with loteprednol etabon-
ate had less effect on IOP elevation than prednisolone.
The mean (SD) IOP on the final visit was 12 (3) mmHg
in the loteprednol etabonate group compared with 16
(1) mmHg in the prednisolone group. C¸oban and
Kocak [32] also compared the safety of loteprednol
etabonate 0.5 % and prednisolone acetate 1 % in 40
patients after uncomplicated phacoemulsification sur-
gery. Treatments were administered five times daily
from the first day postoperatively, and patients were
evaluated at 1 day, 1 week, and 1 month thereafter. At
all postoperative visits, the mean IOP was lower in the
loteprednol etabonate group than in the prednisolone
group. The authors concluded that loteprednol etabon-
ate 0.5 % use after cataract surgery is associated with a
smaller increase in IOP than prednisolone use.
As indicated above, in most instances, topical
corticosteroids are used in combination with NSAIDs
for the treatment of pain and postoperative inflamma-
tion. Macri et al. [25] compared the use of loteprednol
etabonate 0.5 % alone, loteprednol etabonate 0.5 % in
combination with indomethacin 0.1 %, and dexameth-
asone disodium phosphate 0.15 % in the treatment of
postoperative inflammation following uncomplicated
cataract surgery. Patients were divided into three
groups, the first of which included 79 patients
administered indomethacin 0.1 % from 3 days before
to 2 weeks after surgery and loteprednol etabonate for
510 Int Ophthalmol (2012) 32:507–517
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4 weeks after surgery. The second and third groups
comprised 81 patients treated with loteprednol eta-
bonate 0.5 % for 4 weeks and 78 patients treated with
dexamethasone for 4 weeks, respectively. All three
therapeutic regimens were effective in preventing
postoperative ocular inflammation at postoperative
weeks 1 and 4 with very mild ACI and very low
corneal fluorescein staining in all 3 groups. Two cases
of IOP elevation (both in the dexamethasone group)
and three cases of CME (loteprednol etabonate
group = 1, and dexamethasone group = 2) were
observed. The authors concluded that there was better
control of IOP and prevention of CME in the
combination group but that larger confirmatory studies
were needed.
Loteprednol etabonate: additional safety studies
The above studies establish the efficacy and/or safety
of loteprednol etabonate 0.5 % for the treatment of
postoperative inflammation in prospective, random-
ized, double-masked studies. Additional published
studies provide insight into the safety of long-term
treatment with loteprednol etabonate and safety of
loteprednol etabonate in steroid responders.
Howes et al. [33] studied the systemic pharmaco-
kinetics, systemic effects, and IOP effects of lotepred-
nol etabonate 0.5 % after chronic ocular
administration in a double-masked study. Healthy
individuals aged 19–44 years were randomized to
receive either loteprednol etabonate (n = 10) or
vehicle (n = 4) instilled in each eye every 2 h while
awake (8 times a day) on days 0 and 1 and four times
daily on days 2 through to 42. Blood samples were
collected at 0, 15, 30, 60, and 120 min after the first
and eighth doses on day 0 and after the fourth dose on
day 42, and once on days 7, 14, and 28. Plasma levels
of loteprednol etabonate and D1 cortienic acid etabon-
ate were below the level of quantitation (1 ng/mL) in
all samples collected, while cortisol levels were all
within normal range indicating a lack of hypotha-
lamic–pituitary–adrenal axis suppression. None of the
patients exhibited a clinically significant increase in
IOP (C10 mmHg) over the 6 week study period.
Holland et al. [34] compared the effects of a combi-
nation of loteprednol etabonate and tobramycin (LE/
T) with that of dexamethasone and tobramycin (DM/
T) on IOP in healthy volunteers over a 4 week
treatment period. A total of 306 volunteers were
randomized to receive either LE/T or DM/T admin-
istered every 4 h for 28 days. Clinically significant
increases in IOP (C10 mmHg) were observed in three
(1.95 %) subjects treated with LE/T compared with 11
(7.48 %) subjects treated with DM/T (P = 0.028).
Finally, Novack et al. [35] assessed the long-term
safety of loteprednol etabonate across all development
studies of loteprednol etabonate (0.2 and 0.5 %
suspension) in a large retrospective analysis. These
development studies included the use of loteprednol
etabonate for postoperative inflammation as well as
other ocular inflammatory conditions (seasonal aller-
gic conjunctivitis, giant papillary conjunctivitis, and
uveitis). Data from 1,648 patients treated with lote-
prednol for C28 days was reviewed. The proportion of
patients exhibiting clinically significant increases in
IOP (C10 mmHg) was 0.5, 1.7, and 6.7 % with
vehicle, loteprednol etabonate, and prednisolone ace-
tate 1 % (used as a comparator in some studies),
respectively. Excluding patients that continued to
wear contact lenses (allowed in giant papillary con-
junctivitis studies), the proportions of patients show-
ing clinically significant increases in IOP were 1.0,
0.6, and 6.7 % for vehicle, loteprednol etabonate, and
prednisolone acetate 1 %, respectively. In studies with
loteprednol etabonate 0.5 %, the proportion of
patients with a clinically significant increase in IOP
was 2.1 % if patients wearing contact lenses were
included and 0.8 % if these patients were excluded.
In addition to the above studies on the safety of
loteprednol etabonate with long-term use, two studies
in steroid responders support the relative lack of impact
of loteprednol etabonate on IOP. In a retrospective
review, Holland et al. [36] evaluated data from 30 post-
penetrating keratoplasty and post-keratolimbal allo-
graft patients who, after experiencing increased IOP to
C21 mmHg, were switched from prednisolone acetate
1 % to loteprednol etabonate 0.5 %. Results showed a
mean (SE) reduction of IOP from 31.1 (1.13) mmHg
on prednisolone acetate to 18.2 (1.37) mmHg on
loteprednol etabonate (P \ 0.001) and no allograft
rejection. Bartlett and colleagues examined the safety
of loteprednol etabonate in a crossover study in 19
known steroid responders. Subjects received either
loteprednol etabonate or prednisolone acetate 1.0 %
for 42 days followed by a washout period of 14 days
prior to being crossed over to the other treatment [37].
During treatment with loteprednol etabonate, IOPs
Int Ophthalmol (2012) 32:507–517 511
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were within the normal range, with a mean IOP
elevation of 4.1 mmHg over the 42 day period (NS vs
baseline). In contrast, the subjects’ IOPs were signif-
icantly greater compared to baseline during treatment
with prednisolone acetate; mean IOP elevations of 5.9,
7.7, and 9.0 mmHg were observed by days 14, 28, and
42, respectively (P \ 0.05 for all).
Taken together, the available clinical efficacy and
safety studies of loteprednol etabonate 0.5 % for the
treatment of postoperative inflammation, combined
with safety studies on the long-term use of loteprednol
etabonate or use of loteprednol etabonate in steroid
responders suggest that loteprednol etabonate is a
potent and safe topical corticosteroid with a low
propensity to increase IOP relative to older corticoste-
roids such as prednisolone acetate or dexamethasone.
Loteprednol etabonate: comparison
with rimexolone
Rimexolone is a C-20 ketone steroid similar to
prednisolone with the 17a-hydroxyl group replaced
with a methyl group and an additional methyl group at
the C16 position [38]. While it has been granted
regulatory approval in the United States, rimexolone
has not received approval in all countries in the
European Union. Bron et al. [39] assessed the safety
and efficacy of rimexolone 1 % ophthalmic suspension
compared with placebo for reducing postoperative
inflammation after cataract surgery and IOL implan-
tation. In this study, 182 post-cataract patients were
randomized to rimexolone 1 % or placebo instilled
four times daily for 14 days postoperatively. As was
the case in studies with loteprednol etabonate, inclu-
sion criteria included a Grade C3 (0–9 scale) for the
sum of cells and flare combined on the day following
cataract surgery. By the final visit, the proportion of
patients with resolution of inflammation (B5 cells and
none-to-trace flare) was 59.7 and 27.6 % for the
rimexolone and placebo group, respectively (32 %
difference; P \ 0.0001). Supportive measures of
ocular discomfort, corneal edema, bulbar conjunctival
erythema, anterior vitreous reaction and the physi-
cian’s impression all favored treatment with rimexo-
lone (P \ 0.05). The authors reported no perceptible
change in IOP in either group at any visit but indicated
that the study was not designed to show differences in
IOP. A similar study was conducted by Assil et al. [7].
In this study, 197 patients with combined cell and flare
severity C3 for cells and flare combined (0–9 scale)
24 h after cataract surgery were randomized to
rimexolone 1 % or placebo four times daily for
14 days. Consistent with the study by Bron et al.,
59.7 % of patients in the rimexolone group compared
to 32.1 % of patients in the placebo group had their
inflammation resolved by the final visit (27.6 %
difference, P \ 0.001). Secondary measures of bulbar
conjunctival erythema, and the physician’s follow-up
impression also favored rimexolone treatment com-
pared to placebo treatment (P \ 0.05) although there
was no between-group difference in the presence of
ciliary flush or anterior vitreous reaction. Mean IOP
decreased relative to baseline (postoperative day 1) in
both treatment groups, although two patients in each
treatment group experienced a clinically significant
increase in IOP (C10 mmHg). Based on the treatment
effects noted in these studies, the clinical efficacy
observed with rimexolone appears similar to that
observed in vehicle-controlled studies with lotepred-
nol etabonate.
Several published studies compared the clinical
efficacy and safety of rimexolone 1 % to prednisolone
acetate 1 %. Kavuncu et al. [40] compared the efficacy
of rimexolone to prednisolone, administered four times
daily for 15 days postoperatively for the treatment of
postoperative ocular inflammation in 80 post-cataract
patients (baseline inflammation severity not specified).
Both treatments were effective in reducing postopera-
tive inflammation, with no between-group differences in
anterior chamber cell count or flare severity at any
postoperative visit (days 1, 3, 8, 15, 18). However,
conjunctival hyperemia was worse in the rimexolone
group on days 1 and 3 (P \ 0.05), while corneal edema
was worse in the prednisolone group on day 8
(P \ 0.05). There were also no between-group differ-
ences in IOP, with mean (SD) final visit IOPs of 12.96
(3.2) mmHg and 11.65 (2.86) mmHg, respectively.
Yaylali et al. [41] also evaluated the anti-inflammatory
efficacy of rimexolone with that of prednisolone acetate
1 %, both administered four times daily for 15 days, in
patients (n = 48) undergoing cataract extraction by
phacoemulsification. There was no difference between
treatment groups in mean inflammation scores (aqueous
cell, flare, and conjunctival hyperemia individually) at
postoperative follow-up visits except for cells at post-
operative day 3 which were lower in the prednisolone
group. Although mean IOP decreased in both groups
512 Int Ophthalmol (2012) 32:507–517
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relative to postoperative day 1, a significant difference
between treatments was found at postoperative day 3,
with mean (SD) IOPs of 10.9 (1.3) mmHg and 11.9
(1.9) mmHg in the rimexolone and prednisolone
groups, respectively. There were no differences between
treatments in mean IOP at days 7 or 15. Furthermore,
Hirneiss et al. [42] compared the clinical efficacy and
safety of rimexolone with that of prednisolone and
ketorolac tromethamine in 45 patients after cataract
extraction. There was no difference between treatments
in control of aqueous cells, but prednisolone was more
effective than rimexolone in controlling flare and
conjunctival hyperemia. Notably, one patient from the
prednisolone group was discontinued for a marked early
increase in IOP.
Finally, Leibowitz et al. [38] studied the IOP-
increasing potential of rimexolone 1.0 % with that of
fluorometholone alcohol 0.1 % in a double-masked,
two-way crossover study of 45 otherwise healthy
steroid responders. Following verification of steroid
responder status with either dexamethasone or pred-
nisolone acetate, subjects were randomized to either
rimexolone or fluorometholone administered every
2 h for 2 days followed by four times daily for
40 days. On completion of the 6 week study duration
or on exhibiting an increase in IOP of C10 mmHg, the
study treatment was stopped; subjects completed a
1 month washout and then received the alternate
treatment for another 6 weeks. There was no signif-
icant difference between rimexolone and fluorometh-
olone in the number of subjects demonstrating an
increase in IOP of C10 mmHg or in the number of
weeks required to achieve a 10 mmHg increase.
Rimexolone treatment resulted in a mean increase in
IOP of 7.5 mmHg in patients previously observed to
have a mean increase of 11.8 mmHg with dexameth-
asone (P = 0.001), and a mean increase of 6.2 mmHg
in patients previously observed to have a mean
increase of 12.1 mmHg with prednisolone acetate
(P \ 0.001). As noted above, a similar cross-over
study with loteprednol etabonate resulted in a mean
IOP elevation of 4.1 mmHg over a six-week period
(NS vs baseline) compared to 9.0 mmHg for prednis-
olone acetate (P \ 0.05 vs baseline) [37]. Table 2
compares the efficacy and safety parameters evaluated
in the above-mentioned studies on rimexolone.
In summary, vehicle-controlled studies with rim-
exolone suggested similar treatment effects compared
to loteprednol etabonate for the control of postoper-
ative inflammation with minimal IOP impact.
Table 2 Studies demonstrating the efficacy and safety of rimexolone 1 % for postoperative inflammation
Study parameters Bron et al.
[39]






Comparator Placebo Placebo PA PA PA and ketorolac
No. of patients 182 197 80 48 45
Treatment duration
(weeks)
2 Up to 2 2 2 4
Patients with
resolution of ACIa
at final visit ( %)
Rimexolone—
60 %














13.0 ± 3.2 mmHg
Rimexolone—






11.7 ± 2.9 mmHg
PA group—






Not reported n = 2 for rimexolone; Not reported Not reported Not reported
n = 2 for placebo
ACI anterior chamber inflammation, IOP intraocular pressure, PA prednisolone acetate
a Resolution of ACI defined as anterior chamber cell count \5 and flare Grade 0 (none)
b The study did not report the percentages of patients with resolution of ACI; instead, mean cell and flare at study visits were reported
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However, contrary to comparative studies with lote-
prednol etabonate, studies comparing rimexolone with
prednisolone acetate suggest rimexolone’s clinical
efficacy may not be as robust as that of prednisolone.
Loteprednol etabonate: comparison
with difluprednate
Difluprednate ophthalmic emulsion, 0.05 %, has also
been approved for postoperative anti-inflammatory use
in the United States. Like loteprednol etabonate,
difluprednate is a derivative of prednisolone. Structural
modifications include the addition of fluorine atoms at
both the C-6 and C-9 positions, a butyrate ester at the
C-17 position and acetate ester at the C-21 position
(Fig. 2) [43]. However, difluprednate retains the C-20
ketone moiety of prednisolone. Korenfeld et al. [8]
evaluated the safety and efficacy of difluprednate
0.05 % versus placebo for postoperative inflammation
in two identical double-masked, placebo-controlled
studies. Patients (n = 438) with anterior chamber cell
grade C2 one day after ocular surgery were random-
ized to difluprednate twice daily, difluprednate four
times daily or placebo (n = 110 in each study) for
14 days followed by a 14 day tapering period. Primary
assessment included the resolution of anterior chamber
cells, proportion of patients with clinical response, and
absence of pain/discomfort. For comparative purposes,
only the proportion of patients with clinical response
(defined as B5 cells and no flare) is summarized here.
By day 15, clinical response was observed in 72.7 % of
patients receiving difluprednate twice daily and
71.0 % of patients receiving difluprednate four times
daily compared to approximately 27 % of patients
receiving placebo (difference *45 %, P \ 0.0001 vs
placebo). Proportions for pain-free patients and sec-
ondary measures of photophobia, chemosis, corneal
edema, and conjunctival injection were all signifi-
cantly better in the difluprednate groups compared to
placebo groups. In terms of safety, mean IOP remained
within normal range in all treatment groups; however,
three patients (3 %) in each of the difluprednate
treatment groups experienced clinically significant
increases in IOP compared with two patients (1 %) in
the placebo group. Smith et al. [44] studied the clinical
efficacy of difluprednate administered twice daily for
managing ocular inflammation and pain following
cataract surgery. Patients (n = 121) were randomized
to receive either difluprednate or placebo twice daily
for 16 days; this was followed by a 14 day tapering
period. This study differed from previous studies in
that dosing was initiated 24 h before ocular surgery.
Resolution of cells (B5 cells) and Grade 0 flare was
observed in 74.7 % of difluprednate patients compared
to 42.5 % of placebo patients (difference = 32 %;
P = 0.0006). Significant differences were also
observed between the two groups in the proportions
of patients that were free of ocular pain and discomfort
(difference = 34.6 %; P = 0.0004). As in the study
by Korenfeld et al. [8], three subjects (3.7 %) in the
difluprednate group had a clinically significant
increase in IOP (C10 mmHg). Further details of the




Fig. 2 Structures of loteprednol etabonate (a), rimexolone
(b) and difluprednate (c)
514 Int Ophthalmol (2012) 32:507–517
123
In summary, while the above placebo-controlled
studies suggest difluprednate has a similar treatment
effect to loteprednol etabonate, the impact of diflupred-
nate on IOP may be greater. Indeed, Cable [45] reported
significant elevations of IOP in patients undergoing
uncomplicated cataract surgery administered diflupred-
nate twice daily following surgery. In this retrospective
chart review of 100 consecutive patients, 5 % of patients
responded with ocular hypertension. All patients had a
history of open-angle glaucoma, but were not known
steroids responders, and the average increase in IOP was
17.8 mmHg. The IOP increases were managed by the
discontinuation of difluprednate, and the administration
of topical glaucoma medication if required. The IOP
returned to baseline in all patients in 1–2 days. In
contrast, IOP of C 10 mmHg was seen on average in
1.4 % of loteprednol etabonate treated patients in
vehicle-controlled clinical studies and as few as 1.7 %
of long-term users of loteprednol etabonate [35, 46].
Figure 3 compares the resolution of cells and flare
in clinical studies of loteprednol etabonate 0.5 %,
rimexolone 1 %, and difluprednate 0.5 % for postop-
erative inflammation following uncomplicated cata-
ract surgery, based on vehicle-controlled studies.
Table 3 Studies demonstrating the efficacy and safety of difluprednate for postoperative inflammation
Study parameters Korenfeld et al. [8] Smith et al. [44]
Comparator Placebo Placebo
No. of patients 438 124
Treatment duration 15 daysa 16 day treatment perioda
Patients with a clinical responseb (%) Difluprednate BID—72.7c Difluprednate—74.7 %
Difluprednate QID—71c Placebo—42.5
Mean IOP at final visit No significant changes from
baseline for the difluprednate
group reported
Not reported
Clinically significant increases in IOP
(C10 mmHg)
n = 3 for difluprednate BID; n = 3 for
difluprednaten = 3 for difluprednate QID;
n = 2 for placebo
ACI anterior chamber inflammation, BID twice daily, QID 4 times daily, IOP intraocular pressure
a The treatment period was followed by a 2 week tapering period before treatment was stopped
b Clinical response defined as anterior chamber cell count \5 and flare Grade 0
c Prior to commencement of dose-tapering
Fig. 3 Resolution of cells
and flare in clinical studies
of loteprednol etabonate
0.5 %, rimexolone 1 %, and




of cells and flare was defined
as C5 cells and none-to-
trace flare in loteprednol
etabonate and rimexolone
studies and\5 cells and no
flare in difluprednate studies
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Conclusion
As evidenced by a comprehensive review of the data
from published studies, loteprednol etabonate is effec-
tive in resolving anterior chamber cells and flare as well
as in reducing postoperative pain and discomfort. Based
on the available data, loteprednol etabonate offers
efficacy similar to older corticosteroids such as pred-
nisolone acetate, with a much-reduced effect on IOP,
thereby presenting an improved safety profile as com-
pared to these older compounds. Extensive searches
through the available literature have demonstrated a
lack of direct head-to-head studies comparing lotepred-
nol etabonate to other newer corticosteroids (such as
rimexolone and difluprednate) formally approved for
this indication. In order to address this gap, we compared
the relative safety and efficacy of loteprednol etabonate
with these newer corticosteroids across vehicle-con-
trolled studies and by examining data from studies in
which these compounds were compared to older
corticosteroids. Based on our results, loteprednol
etabonate provides similar efficacy to rimexolone and
difluprednate by offering similar rates of resolution of
ocular inflammation. The use of loteprednol etabonate,
however, seems to be associated with fewer clinically
significant increases in IOP (C10 mmHg), thereby
reducing the risk of corticosteroid-induced ocular
hypertension and eventual corticosteroid-induced glau-
coma. While these results provide significant insights
into the effects of these newer corticosteroids, high
quality, active-controlled, randomized clinical trials
between these compounds are needed to assess their
comparative safety and efficacy.
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